Isolation of a high‐affinity Bet v 1‐specific IgG‐derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments

BACKGROUND: Recombinant hypoallergenic allergen derivatives have been used in clinical immunotherapy studies, and clinical efficacy seems to be related to the induction of blocking IgG antibodies recognizing the wild‐type allergens. However, so far no treatment‐induced IgG antibodies have been chara...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadermaier, E., Marth, K., Lupinek, C., Campana, R., Hofer, G., Blatt, K., Smiljkovic, D., Roder, U., Focke‐Tejkl, M., Vrtala, S., Keller, W., Valent, P., Valenta, R., Flicker, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032869/
https://www.ncbi.nlm.nih.gov/pubmed/29315611
http://dx.doi.org/10.1111/all.13394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032869/
https://www.ncbi.nlm.nih.gov/pubmed/29315611
http://dx.doi.org/10.1111/all.13394

Ejemplares similares